CORONA Remedies Limited has announced its unaudited financial results for the second quarter and half-year ended September 30, 2026. The company reported revenue from operations of ₹441.17 crore for the quarter and ₹863.60 crore for the half-year. Net profit after tax for the quarter stood at ₹60.18 crore, while the half-year net profit was ₹120.28 crore. These results were approved by the Board of Directors and are available on the company’s website.
CORONA Remedies Reports Q2 and H1 FY27 Financials
CORONA Remedies Limited has published its unaudited financial results for the second quarter and the half-year ended September 30, 2026. The Board of Directors approved these results at a meeting held on October 30, 2026.
Q2 FY27 Performance
For the quarter ended September 30, 2026, CORONA Remedies reported total income of ₹443.65 crore, with revenue from operations contributing ₹441.17 crore. Total expenses for the quarter amounted to ₹363.03 crore. The profit before tax was ₹80.62 crore, and after accounting for a tax expense of ₹20.44 crore, the net profit after tax for the quarter stood at ₹60.18 crore. Total comprehensive income for the quarter was ₹59.46 crore.
H1 FY27 Performance
For the half-year ended September 30, 2026, the company’s total income reached ₹869.23 crore, with revenue from operations at ₹863.60 crore. Total expenses for the half-year were ₹708.26 crore. The profit before tax for the half-year was ₹160.97 crore. After a tax expense of ₹40.69 crore, the net profit after tax for the half-year was ₹120.28 crore. Total comprehensive income for the half-year was ₹119.26 crore.
Balance Sheet Highlights
As of September 30, 2026, the company’s total assets stood at ₹1,245.70 crore. Total equity was ₹804.07 crore, comprising equity share capital of ₹61.16 crore and other equity of ₹742.91 crore. Total liabilities were ₹441.63 crore.
Cash Flow Statement Summary
The net cash generated from operating activities for the half-year ended September 30, 2026, was ₹112.73 crore. Investing activities used a net cash of ₹3.30 crore, while financing activities used ₹116.28 crore. The net decrease in cash and cash equivalents for the period was ₹0.25 crore.
Other Disclosures
The financial results include a note regarding the listing of the company’s equity shares on the National Stock Exchange of India and BSE Limited on December 15, 2025. The results have been reviewed by the Audit Committee and approved by the Board of Directors.
Source: BSE
